Patents Assigned to Sunesis Pharmaceuticals, Inc.
  • Pyrimidinyl tyrosine kinase inhibitors
    Patent number: 9394277
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 19, 2016
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Brian T. Hopkins, Patrick Conlon, Timothy R. Chan, Tracy J. Jenkins, Xiongwei Cai, Michael Humora, Xianglin Shi, Ross A. Miller, Andrew Thompson
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9353087
    Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 31, 2016
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Brian T. Hopkins, Xiongwei Cai, Timothy R. Chan, Patrick Conlon, Michael Humora, Tracy J. Jenkins, Michael J. Macphee, Xianglin Shi, Ross A. Miller, Andrew Thompson
  • Heterocyclic tyrosine kinase inhibitors
    Patent number: 9273028
    Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: March 1, 2016
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Brian T. Hopkins, Daniel Scott, Patrick Conlon, Tracy J. Jenkins, Noel Powell, Bing Guan, Julio H. Cuervo, Deping Wang, Art Taveras
  • Bruton'S tyrosine kinase inhibitors
    Patent number: 9249146
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: February 2, 2016
    Assignees: Biogen MA Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Heteroaryl Btk inhibitors
    Patent number: 9029359
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 12, 2015
    Assignees: Biogen Idec MA, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Minna Bui, Patrick Conlon, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Alexey Ishchenko, Tracy J. Jenkins, Gnanasambandam Kumaravel, Doug Marcotte, Noel Powell, Daniel Scott, Art Taveras, Deping Wang, Min Zhong
  • SNS-595 AND METHODS OF USING THE SAME
    Publication number: 20140378505
    Abstract: The present invention relates to SNS-595 and of treating cancer using the same.
    Type: Application
    Filed: February 3, 2014
    Publication date: December 25, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Daniel C. ADELMAN, Jeffrey A. Silverman
  • STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20140275547
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Henggin Cheng
  • SNS-595 and methods of using the same
    Patent number: 8822493
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 2, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
  • Method of preparing (+)-1,4-dihydro-7-[(3,4)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
    Patent number: 8802719
    Abstract: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 12, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Tamilarasan Subramani, Mohamed Shiek Mohamed Mujeebur Rahuman, Ramar Subbiah
  • Compounds useful as Raf kinase inhibitors
    Patent number: 8802657
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: August 12, 2014
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Jennifer Cossrow, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
    Publication number: 20140205679
    Abstract: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.
    Type: Application
    Filed: August 21, 2013
    Publication date: July 24, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventor: Jeffrey A. Silverman
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER
    Publication number: 20140205680
    Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: October 17, 2013
    Publication date: July 24, 2014
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman, Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
  • Bruton's tyrosine kinase inhibitors
    Patent number: 8785440
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: July 22, 2014
    Assignees: Biogen Idec MA, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Pyridinonyl PDK1 inhibitors
    Patent number: 8778977
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: July 15, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • 1,8-naphthyridine compounds for the treatment of cancer
    Patent number: 8765954
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: July 1, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • SNS-595 and methods of using the same
    Patent number: 8669270
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 11, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Sunesis Pharmaceuticals, Inc.
    Inventors: Masaru Higaki, Satoshi Nakao
  • HETEROCYCLIC TYROSINE KINASE INHIBITORS
    Publication number: 20130345192
    Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2011
    Publication date: December 26, 2013
    Applicants: SUNESIS PHARMACEUTICALS, INC., BIOGEN IDEC MA INC.
    Inventors: Brian T. Hopkins, Daniel Scott, Patrick Conlon, Tracy J. Jenkins, Noel Powell, Bing Guan, Julio H. Cuervo, Deping Wang, Art Taveras
  • Stable SNS-595 compositions and methods of preparation
    Patent number: 8586601
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: November 19, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
    Patent number: 8580814
    Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: November 12, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman
  • SNS-595 AND METHODS OF USING THE SAME
    Publication number: 20130244967
    Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 19, 2013
    Applicant: Sunesis Pharmaceuticals, Inc.
    Inventors: MICHELLE ARKIN, JENNIFER HYDE, DUNCAN WALKER, JASMIN WRIGHT